• Raising up to $2.062 million through a 1-for-5 non-renounceable rights issue
• Funds to support growth initiatives and commercial rollout of NeuroStrip and NeuroNode
• Partially underwritten to $1,150,610 by major shareholders and CEO

Control Bionics Ltd is conducting a 1-for-5 non-renounceable rights issue to raise up to approximately $2.062 million (before costs). The funds raised will be used to support the company's established growth initiatives, including a more robust commercial rollout of NeuroStrip and expansion of operational capacity with the NeuroNode Only strategy. The company is actively negotiating distribution partnerships for the NeuroNode, with one or more agreements anticipated to conclude in Q2FY26. While NeuroBounce customer acquisition has progressed more slowly than expected, the company remains confident in securing initial customer contracts before the end of 2025. The rights issue is partially underwritten to $1,150,610 by the company's two largest shareholders, Nightingale Partners Pty Limited and Phoenix Development Fund Limited, as well as Start Beyond Pty Limited and the company's CEO, Jeremy Steele. Any New Shares not taken up by Eligible Shareholders will form part of the shortfall, which the Directors reserve the right to place with Eligible Shareholders who apply for Additional New Shares or other investors within 3 months after the close of the rights issue.

After a record growth year in FY25 (unaudited), the company is accelerating the rollout of the NeuroStrip through targeted investment in tooling and infrastructure to meet anticipated volume demand for its devices and supporting software platforms.